High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On


Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge. In order to improve virologic response and reduce the risk of decompensation, we evaluate the efficacy of a… (More)
DOI: 10.1007/s10620-011-1873-x


4 Figures and Tables